Cancer Family
Head and Neck Neoplasm
CI-CAN-00000021Explore in graph →
Non-malignant1,572 active trials17 approved drugs142 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000021Explore in graph →
Clinical trials
6,373 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04782856 | Energy Metabolism in Thyroidectomized Patients | completed | Phase 2 | 13 | Virginia Commonwealth UniversityOTHER | 1 | Jun 14, 2024 | clinicaltrials |
| NCT06446570 | Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma | completed | Phase 2 | 18 | Seoul National University HospitalOTHER | 1 | Jun 6, 2024 | clinicaltrials |
| NCT03038308 |
| Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole |
| completed |
| Phase 1 / Phase 2 |
| 16 |
| Columbia UniversityOTHER |
| 1 |
| Jun 4, 2024 |
| clinicaltrials |
| NCT04396886 | Bintrafusp Alfa in Previously Treated Patients With R/M Non-keratinizing NPC | completed | Phase 2 | 38 | The University of Hong KongOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT03025958 | Radiation Plus Concurrent Nimotuzumab in Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma | completed | Phase 2 | 30 | Zhejiang Cancer HospitalOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT03077243 | P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC | completed | Phase 2 | 195 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT04742959 | Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 203 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Apr 26, 2024 | clinicaltrials |
| NCT04939480 | Window of Opportunity Study of Preoperative Immunotherapy With Atezolizumab in Local SCCHN(PIONEER) | completed | Phase 2 | 20 | University Hospital, EssenOTHER | 1 | Apr 25, 2024 | clinicaltrials |
| NCT03723967 | FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/Paclitaxel(FRAIL-IMMUNE) | completed | Phase 2 | 104 | Centre Leon BerardOTHER | 1 | Apr 22, 2024 | clinicaltrials |
| NCT00537095 | Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer | completed | Phase 2 | 164 | Genzyme, a Sanofi CompanyINDUSTRY | 7 | Apr 19, 2024 | clinicaltrials |
| NCT03565536 | Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer | completed | Phase 2 | 18 | Fujian Medical UniversityOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT03426657 | Radiotherapy With Double Checkpoint Blockade of Locally Advanced HNSCC | completed | Phase 2 | 120 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT03558191 | SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy. | completed | Phase 2 | 156 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Mar 15, 2024 | clinicaltrials |
| NCT03665285 | A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 109 | NextCure, Inc.INDUSTRY | 1 | Mar 8, 2024 | clinicaltrials |
| NCT01979211 | Post-operative Radiation With Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 24 | University of CincinnatiOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT03012581 | Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types(AcSé) | completed | Phase 2 | 269 | UNICANCEROTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT03012620 | Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types(AcSé) | completed | Phase 2 | 334 | UNICANCEROTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT04221165 | Opioid Therapy vs Multimodal Analgesia in Head and Neck Cancer | completed | Phase 2 | 49 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT01330446 | Single Agent Armodafinil for Patient-Reported Fatigue Following Radiation Therapy for Head and Neck Cancer | completed | Phase 1 / Phase 2 | 26 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 14, 2024 | clinicaltrials |
| NCT03549494 | Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction | completed | Phase 2 | 45 | Catalysis SLINDUSTRY | 1 | Feb 7, 2024 | clinicaltrials |
| NCT00390325 | Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer | completed | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Feb 6, 2024 | clinicaltrials |
| NCT05918224 | Streptococcus Salivarius K12 for Prevention and Treatment of Oral Mucositis in Patients Undergoing Radiotherapy | completed | Phase 2 | 160 | West China HospitalOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT03691207 | A Study Of AL101In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations(ACCURACY) | completed | Phase 2 | 87 | Ayala Pharmaceuticals, Inc,INDUSTRY | 6 | Jan 31, 2024 | clinicaltrials |
| NCT01437449 | Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN) | completed | Phase 2 | 27 | Stanford UniversityOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT02367859 | Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma | completed | Phase 2 | 1 | Stanford UniversityOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT02609386 | IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity(INSPIRE) | completed | Phase 2 | 105 | Brooklyn ImmunoTherapeutics, LLCINDUSTRY | 4 | Jan 30, 2024 | clinicaltrials |
| NCT03511391 | CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors(CHEERS) | completed | Phase 2 | 99 | University Hospital, GhentOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT03543813 | PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL | completed | Phase 1 / Phase 2 | 133 | CytomX TherapeuticsINDUSTRY | 4 | Jan 23, 2024 | clinicaltrials |
| NCT02244463 | A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer | completed | Phase 1 / Phase 2 | 46 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT02865135 | Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer | completed | Phase 1 / Phase 2 | 11 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 11, 2024 | clinicaltrials |
| NCT02718820 | Pembrolizumab Plus Docetaxel for the Treatment of Recurrent or Metastatic Head and Neck Cancer | completed | Phase 1 / Phase 2 | 22 | Medical University of ViennaOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT03749460 | Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers | completed | Phase 1 / Phase 2 | 20 | University of WashingtonOTHER | 1 | Dec 29, 2023 | clinicaltrials |
| NCT03894891 | Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer | completed | Phase 2 | 6 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT01172470 | Phase II Trial of Pemetrexed-Based Induction Chemotherapy Followed by Concomitant Chemoradiotherapy in Previously Irradiated Head and Neck Cancer Patients | completed | Phase 2 | 34 | University of ChicagoOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT01185158 | A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma | completed | Phase 2 | 46 | University of ChicagoOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT02178436 | Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 15 | Mohammed Najeeb Al HallakOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT03906058 | Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line Therapy | completed | Phase 2 | 39 | Sun Yat-sen UniversityOTHER | 1 | Oct 25, 2023 | clinicaltrials |
| NCT03003637 | ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck Carcinoma(IMCISION) | completed | Phase 1 / Phase 2 | 33 | The Netherlands Cancer InstituteOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT01703455 | Activity of Sorafenib in Salivary Gland Cancer | completed | Phase 2 | 37 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Oct 19, 2023 | clinicaltrials |
| NCT01914900 | Preoperative TPF Chemotherapy in Molecularly Selected Locally Advanced Resectable Oral Cavity Squamous Cell Cancer | completed | Phase 2 | 14 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Oct 19, 2023 | clinicaltrials |
| NCT01711658 | TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer.(TRYHARD) | completed | Phase 2 | 142 | Radiation Therapy Oncology GroupNETWORK | 2 | Oct 17, 2023 | clinicaltrials |
| NCT03267121 | A Study of Apatinib and Tegafur Gimeracil Oteracil in Locally Advanced Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 38 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT03083873 | Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck | completed | Phase 2 | 64 | Iovance Biotherapeutics, Inc.INDUSTRY | 1 | Oct 12, 2023 | clinicaltrials |
| NCT02499120 | Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer | completed | Phase 2 | 125 | PfizerINDUSTRY | 15 | Sep 8, 2023 | clinicaltrials |
| NCT03624231 | Feasibility & Efficacy of Durvalumab+Tremelimumab+RT and Durvalumab+RT in Non-resect. Locally Advanced HPVnegativ HNSCC(DURTRE-RAD) | completed | Phase 2 | 18 | Ulrich KeilholzOTHER | 1 | Aug 31, 2023 | clinicaltrials |
| NCT00079079 | Cisplatin or Carboplatin Combined With Gemcitabine in Locally Advanced, Recurrent, or Metastatic Malignant Salivary Gland Tumor | completed | Phase 2 | 34 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT00542308 | Zalutumumab in Non-curable Patients With SCCHN | completed | Phase 2 | 90 | GenmabINDUSTRY | 11 | Aug 3, 2023 | clinicaltrials |
| NCT01054625 | Zalutumumab Pharmacokinetics (PK) in Squamous Cell Carcinoma of the Head and Neck (SCCHN) | completed | Phase 1 / Phase 2 | 31 | GenmabINDUSTRY | 4 | Aug 3, 2023 | clinicaltrials |
| NCT03602079 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | completed | Phase 1 / Phase 2 | 49 | Klus Pharma Inc.INDUSTRY | 1 | Aug 3, 2023 | clinicaltrials |
| NCT02988817 | Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 306 | GenmabINDUSTRY | 6 | Aug 1, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jun 14, 2024source: clinicaltrials